Relmada Therapeutics, Inc.
General ticker "RLMD" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $28.6M (TTM average)
Relmada Therapeutics, Inc. follows the US Stock Market performance with the rate: 39.2%.
Estimated limits based on current volatility of 4.9%: low 3.79$, high 4.18$
Factors to consider:
- Total employees count: 20 (+42.9%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Dependence on product approval, Operational and conduct risks, Labor/talent shortage/retention, Strategic risks and growth management, Cybersecurity threats
- Current price 363.5% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.26$, 0.86$]
- 2025-12-31 to 2026-12-31 estimated range: [0.18$, 0.63$]
Financial Metrics affecting the RLMD estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -436.94 <= 0.33
- Positive: Shareholder equity ratio, % of 77.53 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 435.30 > -0.66
- Negative: negative Industry operating cash flow (median)
Short-term RLMD quotes
Long-term RLMD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $161.25MM | $103.70MM | $83.89MM |
| Operating Income | $-161.25MM | $-103.70MM | $-83.89MM |
| Non-Operating Income | $4.21MM | $4.91MM | $3.91MM |
| R&D Expense | $113.32MM | $54.81MM | $46.18MM |
| Income(Loss) | $-157.04MM | $-98.79MM | $-79.98MM |
| Profit(Loss)* | $-157.04MM | $-98.79MM | $-79.98MM |
| Stockholders Equity | $140.44MM | $85.36MM | $35.52MM |
| Assets | $152.91MM | $97.55MM | $45.82MM |
| Operating Cash Flow | $-103.80MM | $-51.66MM | $-51.76MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $19.73MM | $50.45MM | $51.56MM |
| Financing Cash Flow | $45.02MM | $-0.10MM | $-0.04MM |
| Earnings Per Share** | $-5.30 | $-3.28 | $-2.65 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.